needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:www.galderma.com.

References


Shridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines.Aesthet Surg J. 2024; 44(12):1330-1340. doi: 10.1093/asj/sjae131.

Ablon G, et al. RelaBoNT-A Treatment of Glabellar Lines and Lateral Canthal Lines of Different Baseline Severity: Subgroup Analyses of Pooled Phase III Study Data. Abstract #0080 presented at TOXINS; January 14-17, 2026; Madrid, Spain.

Cox SE, et al. RelabotulinumtoxinA Treament Improved Moderate to Severe Glabellar Lines and Lateral Canthal Lines Regardless of Baseline Toxin Naivety: Subgroup Analyses of Pooled Ph
=*=*=*=*=*=
当前为第7/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页